Overview:

PD-L1 status and antibody-drug conjugates (ADCs) now anchor frontline treatment selection in metastatic triple-negative breast cancer (mTNBC), but community oncologists face variability in PD-L1 assay choice and scoring thresholds, a rapidly-expanding ADC evidence base spanning monotherapy and immunotherapy-combination strategies, and toxicity profiles that differ by agent. Applying this evidence in daily practice requires clinicians to interpret biomarker results correctly, weigh trial data against real-world patient factors, and coordinate with multidisciplinary colleagues on testing, treatment selection, and adverse event management.

This program will be delivered as a series of 8 live, CME-certified virtual meetings in collaboration with ACCC-affiliated Oncology State Societies, supported by an enduring online activity. Using an interactive, case-based format tailored to community oncology practice, these virtual meetings include expert presentations on recent data from clinical trials of mTNBC, followed by case presentations, discussions and learner question and answers. The initiative is designed to translate evolving clinical evidence into practical, real-world decision-making and support personalized care for patients with mTNBC.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Describe how PD-L1 testing impacts treatment planning and regimen selection in patients with newly diagnosed metastatic triple-negative breast cancer (mTNBC)
• Select appropriate frontline strategies for mTNBC based on PD-L1 status, immunotherapy eligibility, patient preferences, and evolving clinical evidence
• Apply practical approaches to toxicity management, patient communication and workflow integration in community oncology settings

Target Audience:

This educational program is primarily directed toward community-based oncologists, nurses, NPs/APPs, and other healthcare professionals involved in the treatment of TNBC.

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour. 

Acknowledgment of Educational Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Have a question for the PER® team?

Oncology Inquiries: onc-info@gotoper.com

Eye Care Inquiries: eye-info@gotoper.com

Multispecialty Inquiries: multi-info@gotoper.com